[{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Chondroitin Sulfate Sodium","moa":"ELA2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Bioiberica","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Chondroitin Sulfate Sodium","moa":"||ELA2","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Bioiberica","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Bioiberica"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chondroitin Sulfate Sodium","moa":"ELA2","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bioiberica \/ Undisclosed"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Chondroitin Sulfate Sodium","moa":"Glycosaminoglycans","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bioiberica \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Chondroitin Sulfate Sodium","moa":"Neurotrophic factor BDNF precursor form; Glial cell line-derived neurotrophic factor; Vascular endothelial growth factor A, long form; C-C motif chemokine 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Azienda di Servizi alla Persona di Pavia","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Chondroitin Sulfate Sodium","moa":"Neurotrophic factor BDNF precursor form; Glial cell line-derived neurotrophic factor; Vascular endothelial growth factor A, long form; C-C motif chemokine 2","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Azienda di Servizi alla Persona di Pavia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azienda di Servizi alla Persona di Pavia \/ Gnosis by Lesaffre","highestDevelopmentStatusID":"11","companyTruncated":"Azienda di Servizi alla Persona di Pavia \/ Gnosis by Lesaffre"},{"orgOrder":0,"company":"Tedec Meiji Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Chondroitin Sulfate Sodium","moa":"Neurotrophic factor BDNF precursor form; Glial cell line-derived neurotrophic factor; Vascular endothelial growth factor A, long form; C-C motif chemokine 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tedec Meiji Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tedec Meiji Farma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tedec Meiji Farma \/ Undisclosed"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Chondroitin Sulfate Sodium","moa":"Neurotrophic factor BDNF precursor form; Glial cell line-derived neurotrophic factor; Vascular endothelial growth factor A, long form; C-C motif chemokine 2","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bioiberica \/ Undisclosed"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Chondroitin Sulfate Sodium","moa":"Neurotrophic factor BDNF precursor form; Glial cell line-derived neurotrophic factor; Vascular endothelial growth factor A, long form; C-C motif chemokine 2","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bioiberica \/ Undisclosed"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chondroitin Sulfate Sodium","moa":"Neurotrophic factor BDNF precursor form; Glial cell line-derived neurotrophic factor; Vascular endothelial growth factor A, long form; C-C motif chemokine 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Chondroitin Sulfate Sodium","moa":"Neurotrophic factor BDNF precursor form; Glial cell line-derived neurotrophic factor; Vascular endothelial growth factor A, long form; C-C motif chemokine 2","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Chondroitin Sulphate","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bioiberica \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Chondroitin Sulphate
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
